In a groundbreaking advance poised to transform cancer therapeutics, researchers have developed an innovative nucleic acid delivery system capable of targeting tumors beyond the liver with unprecedented precision and efficacy. This cutting-edge platform, described as a modular construct composed entirely of circular nucleic acids, overcomes the longstanding challenges that have hindered systemic delivery of nucleic acid drugs to extrahepatic tissues. It offers an inspiring glimpse into the future of personalized medicine by seamlessly integrating oncogene silencing and immune activation into a single, sophisticated molecule that functions without the need for traditional delivery agents.
Systemic administration of nucleic acid therapeutics has historically struggled with critical obstacles such as rapid degradation in the bloodstream, off-target accumulation, and poor penetration into solid tumors. The liver, due to its unique vascular structure and receptor-mediated uptake pathways, has often been the primary organ accessible to nucleic acid delivery platforms. However, tumors residing in other organs, such as the pancreas or lungs, have remained elusive targets, limiting the clinical impact of RNA-based therapies. Addressing these limitations head-on, the new study introduces what the authors term the “circular functional molecular flare,” a chemically programmable biopolymer with extraordinary stability and targeting capabilities.
The construction of these multifunctional circular nucleic acid polymers is a feat of bioengineering elegance. Using DNA-templated ligase-mediated polymerization, short nucleic acid sequences encoding various functional domains—including tumor-targeting aptamers, oncogene-silencing antisense oligonucleotides, immunostimulatory CpG motifs, and cytotoxic drug conjugates—are precisely hybridized onto circular DNA templates. This templated assembly leads to defined-length polymers wherein each functional component is covalently linked in a predetermined composition, creating a densely functionalized, circular construct that resists degradation and maintains structural integrity in biological milieus.
Crucially, these circular constructs exhibit dramatically improved resistance to exonucleases compared to linear oligonucleotides. By virtue of their topology, circular nucleic acid polymers do not present free ends susceptible to enzymatic attack, enabling prolonged circulation time and enhanced bioavailability in vivo. Furthermore, the presence of multiple aptamer domains enables highly selective binding to cell-surface receptors on tumor cells, facilitating targeted uptake through receptor-mediated endocytosis without requiring conventional transfection reagents, which often introduce toxicity and off-target effects.
Beyond targeting tumor cells, the circular flare platform integrates modules designed to “reprogram” the tumor microenvironment. Incorporation of unmethylated CpG motifs activates antigen-presenting cells by stimulating toll-like receptor 9 (TLR9), a critical pathway for initiating potent innate and adaptive immune responses. Simultaneously, the constructs deliver antisense oligonucleotides aimed at silencing key oncogenic drivers such as the Kirsten rat sarcoma viral oncogene homologue (KRAS), which is frequently mutated in pancreatic ductal adenocarcinoma and acts as a lynchpin of malignant transformation and tumor maintenance.
The synergy between immunostimulatory activation and oncogene silencing is evident in preclinical tumor models. When systemically administered to mice bearing pancreatic tumors, the circular flares induced robust knockdown of KRAS messenger RNA through RNase H-mediated degradation, significantly attenuating tumor growth. In parallel, the activation of tumor-infiltrating antigen-presenting cells and subsequent stimulation of cytotoxic T lymphocytes reshaped the tumor microenvironment from immunosuppressive to immunoreactive. This dual-action mechanism resulted in durable antitumor responses, outperforming conventional monotherapies.
Notably, the platform’s modular design enables facile customization by swapping individual codons within the polymer sequences to target different oncogenes or deliver alternative immunomodulatory agents. This versatility promises rapid adaptation against heterogeneous tumor types or emerging drug resistance mechanisms, potentially transforming how precision oncology protocols are devised and administered. The low toxicity profile observed in murine studies further underscores the clinical promise of this approach.
In addition to therapeutic delivery, the structural stability and programmable valence of these circular nucleic acid flares open exciting avenues for diagnostic imaging and theranostics. By conjugating imaging moieties alongside therapeutic segments, clinicians could, in principle, track drug biodistribution, monitor therapeutic response, and refine dosing strategies in near real-time. Such molecular-level control will be indispensable for pushing beyond the one-size-fits-all paradigm that has constrained nucleic acid medicine.
The meticulous biochemical characterization presented in the study illuminates the underlying principles enabling these advances. Careful sequence design ensures cooperative hybridization for optimal folding and multivalency, while enzymatic ligation solidifies the construct’s topology, preventing dissociation or fragment rearrangement. Functional assays demonstrate concurrent aptamer binding, efficient mRNA cleavage, and immune receptor stimulation, confirming that the multifunctional attributes act synergistically within the intact circular framework.
From a translational standpoint, the chemical synthesis and enzymatic assembly routes portend scalable manufacturing potential, a critical parameter as nucleic acid therapies push toward widespread clinical adoption. The avoidance of viral vectors or complex nanoparticle carriers reduces immunogenicity risks and manufacturing bottlenecks. Moreover, the modularity simplifies regulatory approval pathways by enabling platform-based evaluation frameworks where core structures remain constant while payloads vary.
While further research is required to validate safety and efficacy in human subjects, this modular circular nucleic acid scaffold represents a paradigm shift for RNA therapeutics. It bridges longstanding gaps between molecular specificity, systemic delivery, and immunomodulation—historically seen as distinct challenges—thereby establishing a unified, chemically programmable modality to address solid tumors that have defied previous nucleic acid interventions.
In the rapidly evolving landscape of precision oncology, this technology could enable personalized regimens tailored to individual tumor profiles through rapid synthesis of bespoke circular flares targeting oncogenic mutations and immune checkpoints unique to each patient. The potential to combine tumor gene silencing with in situ immune activation heralds a future where nucleic acid drugs not only intercept cancer at the genetic root but also marshal the patient’s immune system for lasting remission.
Ultimately, the integration of advanced nucleic acid chemistry, enzymatic polymerization, and sophisticated biological targeting exemplifies the new frontier of molecular medicine. The circular functional molecular flare stands as a beacon of innovation, spotlighting how rational design can overcome biological barriers and unlock the therapeutic power of nucleic acids in the fight against cancer and beyond. This pioneering work sets the stage for a new class of modular, multifunctional therapeutics that promise to redefine the boundaries of systemic RNA drug delivery.
Subject of Research: Development of circular nucleic acid constructs for systemic delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumors beyond the hepatic system.
Article Title: Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours.
Article References:
Chi, H., An, K., He, J. et al. Modular nucleic acid-based construct for delivery of immunostimulatory agonists and oncogene-silencing oligonucleotides in tumours. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01652-4
Image Credits: AI Generated
